Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17694160 | 1.00 | CYP2C19 (0.31) | CYP2C19 | |
| SCHEMBL17069142 | 0.96 | — | — | |
| SCHEMBL19447936 | 0.96 | — | — | |
| SCHEMBL8977693 | 0.96 | — | — | |
| SCHEMBL17126836 | 0.96 | — | — | |
| SCHEMBL10017886 | 0.96 | — | — | |
| SCHEMBL14557461 | 0.80 | CYP2C19 (0.33) | CYP2C19 | |
| SCHEMBL12410331 | 0.80 | CYP2C19 (0.33) | CYP2C19 | |
| SCHEMBL15910073 | 0.80 | CYP2C19 (0.33) | CYP2C19 | |
| SCHEMBL30930086 | 0.78 | CYP2C19 (0.41) | CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349539-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICALLY ANISOTROPIC SUBSTANCE | ZEON CORPORATION (JP) | 2017-12-07 | — | — | US | disclosed |
| US-9776954-B2 | Polymerizable compound, polymerizable composition, polymer, and optically anisotropic substance | ZEON CORPORATION (JP) | 2017-10-03 | — | — | US | disclosed |
| US-20150274647-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICALLY ANISOTROPIC SUBSTANCE | ZEON CORPORATION (JP) | 2015-10-01 | — | — | US | disclosed |
| US-20140088283-A1 | PHOSPHORUS-CONTAINING COMPOUNDS AND THEIR PREPARATION PROCESS AND USE | NATIONAL CHUNG HSING UNIVERSITY (TW) | 2014-03-27 | — | — | US | disclosed |
| US-20110166127-A1 | Substituted Benzo-Pyrimido-Tetrazolo-Diazepine Compounds | ARQULE, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-7943584-B2 | Medicinal composition containing diabetes remedy | SANKYO COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7632930-B2 | Oligosaccharide derivative | SANKYO COMPANY LIMITED (JP) | 2009-12-15 | — | — | US | disclosed |
| US-20080194495-A1 | Oligosaccharide Derivative | HONDA TAKESHI | 2008-08-14 | — | — | US | disclosed |
| US-7361744-B2 | Oligosaccharide derivative | SANKYO COMPANY LIMITED (JP) | 2008-04-22 | — | — | US | disclosed |
| US-20080039367-A1 | Medicinal Composition Containing Diabeted Remedy | SANKYO COMPANY, LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039367-A1 | Medicinal Composition Containing Diabeted Remedy | DPP4, IAPP, AMY2A | CYP2C19 1531/4885 |
| US-20080194495-A1 | Oligosaccharide Derivative | MAN1B1, FUT6, MAN2A1 | CYP2C19 1642/4885 |
| US-20110166127-A1 | Substituted Benzo-Pyrimido-Tetrazolo-Diazepine Compounds | THPO, DHFR, BRD4 | CYP2C19 396/4885 |
| US-20150274647-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICALLY ANISOTROPIC SUBSTANCE | PYM1, CCNB2, CCNT1 | CYP2C19 2570/4885 |
| US-20170349539-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICALLY ANISOTROPIC SUBSTANCE | PYM1, CCNB2, CCNT1 | CYP2C19 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.